Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL3308504 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL2399914 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1614041 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Dodecane SCHEMBL1747351 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1190938 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL9107982 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL11904142 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1680974 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Hexadecane SCHEMBL3291441 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL18725336 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4365288-A1 | POLYNUCLEOTIDE AND MEDICINAL COMPOSITION | Kyowa Kirin Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| EP-3778573-B1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-117769598-A | Polynucleotide and pharmaceutical composition | 协和麒麟株式会社 | 2024-03-26 | — | — | CN | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-110603330-B | Oligonucleotide derivative or salt thereof | 协和麒麟株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| CN-115996932-A | New macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2023-04-21 | — | — | CN | disclosed |
| US-11629152-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004103356-A2 | TREATMENT OF EMOTIONAL DYSREGULATION | ELI LILLY AND COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004017977-A2 | 2- (PHENOXYMETHYL)- AND 2- (PHENYLTHIOMETHYL)-MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018440-A1 | BENZYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
| US-6075149-A | FUNGICIDES, INSECTICIDEA AND PESTICIDES FOR PROTECTING CROPS | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| US-5663119-A | FOR USE IN AGRICULTURE | RHONE-POULENC AGROCHIMIE (FR) | 1997-09-02 | — | — | US | disclosed |
| US-5523280-A | TREATING PLANT DISEASES | RHONE-POULENC AGROCHIMIE (FR) | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885LMNA 1695/4885HSD17B10 2015/4885 |
| US-11629152-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885LMNA 1695/4885HSD17B10 2015/4885 |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | ALDH1A1 3394/4885LMNA 1734/4885HSD17B10 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.